论文部分内容阅读
目的探讨胸腺瘤WHO组织学类型与Masaoka病理分期的相关性,总结其治疗经验及预后。方法回顾性分析81例胸腺瘤患者的临床资料,总结其病理分期、组织学类型、临床特点、手术方式、综合治疗措施及生存率等。结果胸腺瘤WHO组织学类型与Masaoka病理分期的相关性有高度统计学意义(P<0.001)。81例患者中完整切除59例,不完整切除16例,开胸探查5例,1例行DSA引导下肿块穿刺活检。局部晚期(Masaoka分期Ⅲ、Ⅳa期)的患者中,8例行放射治疗,15例接受了以铂类为基础的化疗。部分患者术后随访3个月～6年,3年和5年生存率分别为76.8%和61.5%。结论胸腺瘤WHO组织学类型与Masaoka病理分期存在相关性。采取以外科手术治疗为主,结合多学科综合治疗,能使胸腺瘤患者保持较高的3年和5年生存率。
Objective To investigate the correlation between WHO histological type of thymoma and Masaoka pathological stage and to summarize its treatment experience and prognosis. Methods The clinical data of 81 patients with thymoma were retrospectively analyzed. The pathological staging, histological type, clinical features, surgical methods, comprehensive treatment and survival rate were summarized. Results Thymoma WHO histological types and Masaoka pathological staging of a highly statistically significant (P <0.001). Of the 81 patients, 59 cases were completely resected, 16 cases were incompletely resected, 5 cases were detected by thoracotomy, and 1 case underwent DSA guided biopsy. Of the patients with locally advanced (Masaoka Stage III, IVa) patients, 8 received radiotherapy and 15 received platinum-based chemotherapy. Some patients were followed up for 3 months to 6 years, 3-year and 5-year survival rates were 76.8% and 61.5%. Conclusion Thymoma WHO histological type and Masaoka pathological staging correlated. Taken mainly to surgical treatment, combined with multidisciplinary comprehensive treatment, patients with thymoma can maintain a high 3-year and 5-year survival rate.